Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenal Gland Disorders01:27

Adrenal Gland Disorders

1.9K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.9K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

212
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
212
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

52
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
52
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

774
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
774

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iodine in Health and Disease: A Comprehensive Review.

Nutrients·2026
Same author

Aldosterone in Chronic Kidney Disease.

Biomedicines·2025
Same author

Increased carotid intima-media thickness is associated with higher odds of unfavorable outcomes in adults without advanced vascular diseases presenting with non-severe COVID-19 pneumonia: a nested case-control study.

Croatian medical journal·2023
Same author

Rescue treatment of severe lupus myocarditis and proliferative lupus nephritis with immunoadsorption.

Clinical rheumatology·2023
Same author

Croatian study on COVID-19-positive stroke patients during the second wave of the pandemic.

Croatian medical journal·2022
Same author

Impact on Emergency Neurology Department Visits in Pre-COVID-19 and COVID-19 Period. A Single Tertiary Center Study.

Psychiatria Danubina·2022

Related Experiment Video

Updated: Sep 16, 2025

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

23.6K

Primary Aldosteronism and Cognitive Dysfunction: A Case-Control Study.

Jakov Herceg1, Gorana Vukorepa2, Sandra Karanović Štambuk1,3

  • 1School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.

Journal of Clinical Medicine
|July 12, 2025
PubMed
Summary

Primary aldosteronism, a condition of elevated aldosterone, is linked to cognitive impairment. This pilot study found lower scores on the Montreal Cognitive Assessment in patients with primary aldosteronism, suggesting a need for further investigation.

Keywords:
cognitive dysfunctionessential hypertensionmini-mental state examinationmontreal cognitive assessmentprimary aldosteronism

More Related Videos

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.1K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.7K

Related Experiment Videos

Last Updated: Sep 16, 2025

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

23.6K
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.1K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.7K

Area of Science:

  • Endocrinology
  • Neuroscience
  • Cardiovascular Medicine

Background:

  • Primary aldosteronism involves elevated aldosterone, causing hypertension and hypokalemia.
  • Aldosterone's central nervous system effects, including oxidative stress and vascular remodeling, may impair cognition.
  • Mineralocorticoid receptors in the hippocampus suggest a link between primary aldosteronism and cognitive dysfunction.

Purpose of the Study:

  • To investigate the association between primary aldosteronism and cognitive impairment.
  • To compare cognitive function in individuals with primary aldosteronism versus essential hypertension.

Main Methods:

  • Pilot study comparing 15 primary aldosteronism patients with 15 essential hypertension controls.
  • Cognitive function assessed using Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA).
  • Clinical and laboratory data collected, including blood pressure and aldosterone levels.

Main Results:

  • Primary aldosteronism group had higher blood pressure, longer hypertension duration, and lower potassium.
  • No significant difference in MMSE scores between groups.
  • Significantly lower MoCA scores in the primary aldosteronism group (25.1 vs. 27.1, p=0.021).
  • Aldosterone levels significantly impacted MoCA scores, independent of blood pressure or hypertension duration.

Conclusions:

  • This study supports an association between hyperaldosteronism and cognitive dysfunction.
  • Highlights the importance of early detection and targeted treatment for primary aldosteronism.
  • Further research in larger cohorts is warranted to confirm these findings.